PWMG
ANIK icon

Private Wealth Management Group’s Anika Therapeutics ANIK Stock Holding History

Private Wealth Management Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.57K Hold
522
– – ﹤0.01% 617
2025
Q4 		$5.02K Hold
522
– – ﹤0.01% 774
2025
Q3 		$4.91K Buy
+522
New +$4.99K ﹤0.01% 798

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Private Wealth Management Group's ANIK Position: Q1 2026 in Review

Private Wealth Management Group held its Anika Therapeutics (ANIK) position steady in Q1 2026 at 522 shares worth $7.57K. The position accounts for ﹤0.01% of the portfolio, ranked #617.

Private Wealth Management Group first reported a position in ANIK in Q3 2025 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Private Wealth Management Group held 522 shares of Anika Therapeutics worth $7.57K as of Q1 2026.
  • Private Wealth Management Group left its Anika Therapeutics share count unchanged in Q1 2026.
  • Anika Therapeutics made up ﹤0.01% of Private Wealth Management Group's portfolio in Q1 2026, its #617 holding.
  • Private Wealth Management Group first reported a position in Anika Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Private Wealth Management Group's 13F filing for Q1 2026, filed 23 Apr 2026.